Literature DB >> 8548531

Immune complex transfer enzyme immunoassay that is more sensitive and specific than western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens.

S Hashida1, K Hashinaka, I Nishikata, S Oka, K Shimada, A Saito, A Takamizawa, H Shinagawa, S Yano, H Kojima.   

Abstract

Antibody immunoglobulin G (IgG) to human immunodeficiency virus type 1 (HIV-1) in serum was detected by ultrasensitive enzyme immunoassays (immune complex transfer enzyme immunoassays) with recombinant reverse transcriptase (rRT), p17 (rp17) and p24 (rp24) of HIV-1 as antigens and beta-D-galactosidase from Escherichia coli as the label. The immune complex, comprising 2,4-dinitrophenyl-bovine serum albumin-recombinant protein conjugate, antibody IgG to HIV-1, and recombinant protein-beta-D-galactosidase conjugate, was trapped on polystyrene beads coated with affinity-purified (anti-2,4-dinitrophenyl group) IgG, eluted with epsilon N-2,4-dinitrophenyl-L-lysine, and transferred to polystyrene beads coated with affinity-purified (anti-human IgG gamma-chain) IgG. Bound beta-D-galactosidase activity was assayed by fluorometry. The assays were highly reproducible with no serious serum interference, and they were much more sensitive than Western immunoblotting for the corresponding antigens. Signals with rRT, rp17, and rp24 for asymptomatic carriers were at least 56,000-, 680-, and 22-fold higher, respectively, than those for seronegative individuals, and neither indeterminate nor false-positive results were observed, whereas some serum samples were false negative or false positive by Western blotting for p17 and/or p24 antigen. In some cases, seroconversion was detected earlier than by conventional methods. Therefore, these assays are suggested to be more useful than conventional methods not only for the confirmation of antibody IgGs to RT, p17, and p24 of HIV-1 in serum but also for the detection of seroconversion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548531      PMCID: PMC170196          DOI: 10.1128/cdli.2.5.535-541.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  26 in total

1.  What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors?

Authors:  J Genesca; J W Shih; B W Jett; I K Hewlett; J S Epstein; H J Alter
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

2.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Reliable confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) with an enzyme-linked immunoassay using recombinant antigens derived from the HIV-1 gag, pol, and env genes.

Authors:  V L Ng; C S Chiang; C Debouck; M S McGrath; T H Grove; J Mills
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

5.  Sensitivity of western blotting (compared with ELISA and immunofluorescence) during seroconversion after HTLV-III infection.

Authors:  J C Ulstrup; K Skaug; K J Figenschau; I Orstavik; J N Bruun; G Petersen
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321

6.  Markers of HIV infection prior to IgG antibody seropositivity.

Authors:  S L Stramer; J S Heller; R W Coombs; J V Parry; D D Ho; J P Allain
Journal:  JAMA       Date:  1989-07-07       Impact factor: 56.272

7.  Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men.

Authors:  S M Wolinsky; C R Rinaldo; S Kwok; J J Sninsky; P Gupta; D Imagawa; H Farzadegan; L P Jacobson; K S Grovit; M H Lee
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

8.  Viral culture and p24 antigenemia of human immunodeficiency virus (HIV)-infected individuals correlated with antibody profiles determined with recombinant polypeptides of all HIV-1 open-reading frames.

Authors:  A Baur; R Vornhagen; K Korn; H H Sonneborn; B Eberlein; T Harrer; W Brockhaus; G Jahn
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

9.  Reliable detection of individuals seropositive for the human immunodeficiency virus (HIV) by competitive immunoassays using Escherichia coli-expressed HIV structural proteins.

Authors:  G J Dawson; J S Heller; C A Wood; R A Gutierrez; J S Webber; J C Hunt; S A Hojvat; D Senn; S G Devare; R H Decker
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

10.  Development of a confirmatory enzyme-linked immunosorbent assay for HIV-1 antibodies.

Authors:  C S Chiang; T Grove; M Cooper; J Cuan; A Kowalski; K Parcells; M Tsunokawa; M Rosenberg; E Arcuri; S Franklin
Journal:  Clin Chem       Date:  1989-06       Impact factor: 8.327

View more
  14 in total

1.  Rapid formation of the immune complexes on solid phase in the immune complex transfer enzyme immunoassays for HIV-1 p24 antigen and antibody IgGs to HIV-1.

Authors:  S Ishikawa; S Hashida; K Hashinaka; A Adachi; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

2.  Rapid and ultrasensitive enzyme immunoassay (thin aqueous layer immune complex transfer enzyme immunoassay) for HIV-1 p24 antigen.

Authors:  S Ishikawa; S Hashida; K Hashinaka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

3.  Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen.

Authors:  S Hashida; S Ishikawa; I Nishikata; K Hashinaka; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.

Authors:  S Hashida; S Ishikawa; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saito; A Takamizawa; H Shinagawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

5.  Ultrasensitive and rapid enzyme immunoassay (thin aqueous layer immune complex transfer enzyme immunoassay) for antibody IgG to HIV-1 p17 antigen.

Authors:  S Ishikawa; S Hashida; K Hashinaka; A Adachi; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  More sensitive immune complex transfer enzyme immunoassay for antibody IgG to p17 of HIV-1 with shorter incubation time for immunoreactions and larger volumes of serum samples.

Authors:  S Ishikawa; S Hashida; K Hashinaka; M Kojima; A Saito; A Takamizawa; H Shinagawa; S Oka; K Shimada; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

7.  Potential of the immune complex transfer enzyme immunoassay for antigens and antibodies to improve the sensitivity and its limitations.

Authors:  E Ishikawa; S Ishikawa; S Hashida; K Hashinaka
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 8.  More reliable diagnosis of infection with human immunodeficiency virus type 1 (HIV-1) by detection of antibody IgGs to pol and gag proteins of HIV-1 and p24 antigen of HIV-1 in urine, saliva, and/or serum with highly sensitive and specific enzyme immunoassay (immune complex transfer enzyme immunoassay): a review.

Authors:  S Hashida; K Hashinaka; S Ishikawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

9.  Preparations of recombinant HIV-1 p66 antigen to improve the specificity of immune complex transfer enzyme immunoassay of antibody IgG to HIV-1 reverse transcriptase.

Authors:  K Hashinaka; I Nishikata; S Hashida; A Adachi; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

10.  False-positive human immunodeficiency virus antibody test in a dialysis patient.

Authors:  Douglas M Silverstein; Diego H Aviles; V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.